China Sets New Record for Local Drug Approvals in 2021

China Sets New Record for Local Drug Approvals in 2021

DIA Global Forum’s annual review of new drug approvals in China has shown growth in both the number and types of new drugs approved in China from 2019 through 2021: from 34 new chemical drugs and 19 biological products in 2019 to 37 new chemical drugs and 24 biological products in 2021. This podcast explores this growth in the context of the regulatory reform begun in China in 2015. “The annual number of new drug approvals reached a record high of 61 in 2021,” explains Global Forum China Regional Editor Ling Su (Shenyang Pharmaceutical University Yeehong Business School; Venture Partner, Lilly Asia Ventures). “In 2021, among the 61 new drugs approved, 31–slightly over 50 percent–were developed by local companies, and this was the first time that domestic companies received more new drug approvals than foreign companies in a given year.”

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(20)

DIA/Tufts CSDD Research: AI Saving Time in Drug Development

DIA/Tufts CSDD Research: AI Saving Time in Drug Development

DIA and the Tufts Center for the Study of Drug Development (Tufts CSDD), in collaboration with 16 biopharmaceutical companies and CROs, conducted a study to map current use of and experience with arti...

17 Jan 202511min

DIA: Your Partner in Life Sciences Training and Development

DIA: Your Partner in Life Sciences Training and Development

This  podcast by the Drug Information Association (DIA) highlights the significant benefits of investing in professional development programs for employees in the life sciences industry. They emphasiz...

6 Nov 202414min

DIA: Going Beyond the Traditional Definition of Drug Development

DIA: Going Beyond the Traditional Definition of Drug Development

In this DIA 60th anniversary interview, former Board President Ling Su shares his thoughts on the two most important aspects of DIA’s future for the next generation of members.

29 Mai 20241min

GPP Experts Explain Authorship Algorithm

GPP Experts Explain Authorship Algorithm

Good Publication Practice (GPP) experts explain the authorship algorithm designed to weigh each author's contribution relative to other authors' contributions in a study, and to define appropriate way...

23 Apr 20247min

"Dossier in the Cloud" Democratizing Global Access

"Dossier in the Cloud" Democratizing Global Access

Accumulus Synergy CEO Francisco Nogueira shares expectations for the outcomes of a post-approval changes pilot led by Roche which utilizes the Accumulus platform and follows WHO principles of good reg...

2 Apr 20242min

DIA: A Place Where You Can Make a Difference

DIA: A Place Where You Can Make a Difference

Listen to former DIA Board President Minnie Baylor-Henry’s special message to DIA members as part of DIA’s 60th Anniversary celebration in 2024.

28 Mar 20241min

Autumn’s Leukemia Story: Regimens, Recovery, and Realizations

Autumn’s Leukemia Story: Regimens, Recovery, and Realizations

A few years ago, 8-year-old Autumn noticed a lump on the side of her neck as she was preparing for bed one night. That quiet night opened a new chapter not only in Autumn’s life but in the life of her...

4 Des 202319min

Retiring TGA Head Maps Australia’s Post-Pandemic Future

Retiring TGA Head Maps Australia’s Post-Pandemic Future

In April 2023, Professor John Skerritt retired after 11 years of exemplary public service as deputy secretary of the Health Products Regulation Group and head of the Therapeutic Goods Administration i...

17 Jul 202318min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
jss
forskningno
liberal-halvtime
rekommandert
sinnsyn
villmarksliv
dekodet-2
tomprat-med-gunnar-tjomlid
smart-forklart
rss-nysgjerrige-norge
fjellsportpodden
rss-kunstig-intelligens-med-elisabeth-maren-og-morten
nevropodden
rss-rekommandert
rss-paradigmepodden
rss-overskuddsliv
abels-tarn
rss-bondevennen